PASADENA, Calif. --(BUSINESS WIRE)--Aug. 18, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 11, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
- Conference Call and Webcast Today, August 5 at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)--Aug. 5, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2020 . The company is hosting a conference call at 4:30 p.m.
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 29, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a Phase 2 clinical study.
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 28, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a key opinion leader webinar today at 12:00 PM EDT on ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 24, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on June 18, 2020 , the Compensation Committee of the Board of Directors approved "inducement" grants to 25 new
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 9, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on July 28, 2020 , at 12:00 p.m. EDT it will host a key opinion leader webinar on ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 8, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2020 , at 4:30 p.m. EDT to discuss its financial results for the fiscal third quarter ended June 30, 2020 .
PASADENA, Calif. --(BUSINESS WIRE)--May 28, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Virtual Healthcare Conference – June 2-4, 2020 June 4 , 2:00 p.m.
- Conference Call and Webcast Today, May 7 at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)--May 7, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2020 . The company is hosting a conference call at 4:30 p.m.